AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$LQDA

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

Original reporting
finance.yahoo.com
Published Nov 10, 2026, 7:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 7:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Liquidia (LQDA) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LQDANeutralHigh
01

Why it matters

The earnings release provides fresh, material data that can drive short-term trading decisions, balancing growth optimism against legal cost concerns.

02

Market read

First-report earnings with significant numbers and a settlement charge make this a high-value trading event for LQDA and related biotech peers.

03

What to watch

Potential future cash flow from upcoming studies and pipeline expansions not yet reflected in price.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Liquidia's Q3 2026 earnings call highlighted rapid sales growth of its inhaled prostacyclin product YUTREPIA, a large settlement charge, and ongoing pipeline developments.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Q3 2026 earnings call disclosed net product sales of $222.7M, a $389.7M settlement charge and GAAP net loss of $236.3M, all first reported.

Expected impact

likely modest downside as investors price in the settlement charge, offset by upside from 31% sales growth and high gross margin.

Evidence & confidence

The settlement charge is a material, non-recurring expense that can depress the stock, while the 31% sales increase and 94% gross margin support a bullish view.

Market effects

Sector

Positive signal for PAH market growth and inhaled prostacyclin segment, may benefit peers.

Regional

US biotech sector may see slight pullback due to settlement charge, but overall sentiment remains supportive of growth.

Global

Limited to investors focused on specialty pharma and biotech earnings.

Counterpoint

What could challenge this read

Settlement charge could signal deeper legal risk, suggesting a more defensive stance.

Key entities

  • Company
    Liquidia

    Biopharma developing inhaled prostacyclin therapies, ticker LQDA.

  • Product
    YUTREPIA

    Inhaled prostacyclin therapy for PAH and PH-ILD.

Read at source← All news

StoryLiquidia reports Q3 2026 loss after $389.7M settlement with United Therapeutics

Also covered by

5 outlets

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com
$LQDAMed

BTIG raises Liquidia stock price target to $87 on strong demand

BTIG raised its price target for Liquidia Technologies (LQDA) to $87 from $70, citing strong demand for Yutrepia and increased 2027 EPS estimates. LQDA's Q3 revenue beat expectations at $225.3M, with Yutrepia sales up 31%, though GAAP EPS loss was $2.64 due to a $389.7M settlement charge. Jefferies also raised its target to $62, maintaining a Buy rating.

investing.com